跳至主要内容
临床试验/IRCT20130812014333N125
IRCT20130812014333N125已完成3 期

One year comparison of effectiveness and complication of rituximab and fingolimod in multiple sclerosis (MS)patients

Kermanshah University of Medical Sciences0 个研究点目标入组 36 人开始时间: 待定最近更新:
适应症

试验速览

阶段
3 期
状态
已完成
入组人数
36

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

年龄范围
18 years 至 55 years(—)
性别
Female

入选标准

  • Age between 18-55 years
  • Negative pregnancy test in women of reproductive age
  • At least one relapse in the past year, despite first-line Dimethyltryptamine treatment
  • At least two relapse in the past two years, despite First-line Dimethyltryptamine treatment
  • Active lesions (a new Type2 (T2) or Gadolinium(GAD) enhancement) and having two or more attacks in the past year despite the first-line treatment in recurrent patients
  • Active lesions (new T2 lesions or GAD enhancement) and attack in patients who have the progressive form of illness

排除标准

  • Acute or chronic bacterial, viral or fungal infection
  • Sensitivity to drug

研究者

相似试验